The Medical Letter on Drugs and Therapeutics
February 25, 2019
- An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
- Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
- Fostamatinib (Tavalisse) for ITP
- Oxybutynin for Hot Flashes in Women with Breast Cancer
- Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
- Elderberry for Influenza
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
February 25, 2019 (Issue: 1566)The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients...more
- Auvi-Q epinephrine auto-injector returns. Med Lett Drugs Ther 2017; 59:33.
- In brief: Auvi-Q epinephrine auto-injector for infants and toddlers. Med Lett Drugs Ther 2018; 60:83.
- RB Moss et al. Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector. Ann Allergy Asthma Immunol 2018; 120:540.
- P Lacwik et al. Single, short-time exposure to heat in a car during sunny day can decrease epinephrine concentration in autoinjectors: a real-life pilot study. J Allergy Clin Immunol Pract 2018 Nov 27 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.